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ABSTRACT
Objective: To quantify the regional and global cerebral atrophy rates and assess acceleration rates in
healthy controls, subjects with mild cognitive impairment (MCI), and subjects with mild Alzheimer
disease (AD).
Methods: Using 0-, 6-, 12-, 18-, 24-, and 36-month MRI scans of controls and subjects with MCI and
AD from theAlzheimer’sDiseaseNeuroimaging Initiative (ADNI) database,we calculated volume change
of whole brain, hippocampus, and ventricles between all pairs of scans using the boundary shift integral.
Results: We found no evidence of acceleration in whole-brain atrophy rates in any group. There was
evidence that hippocampal atrophy rates inMCI subjects accelerate by 0.22%/year2 on average (p5
0.037). There was evidence of acceleration in rates of ventricular enlargement in subjects with MCI
(p5 0.001) and AD (p, 0.001), with rates estimated to increase by0.27mL/year2 (95%confidence
interval 0.12, 0.43) and 0.88 mL/year2 (95% confidence interval 0.47, 1.29), respectively. A post
hoc analysis suggested that the acceleration of hippocampal loss in MCI subjects was mainly driven
by theMCI subjects that were observed to progress to clinical ADwithin 3 years of baseline, with this
group showing hippocampal atrophy rate acceleration of 0.50%/year2 (p 5 0.003).
Conclusions: The small acceleration rates suggest a long period of transition to the pathologic los-
ses seen in clinical AD. The acceleration in hippocampal atrophy rates in MCI subjects in the ADNI
seems to be driven by those MCI subjects who concurrently progressed to a clinical diagnosis of
AD. Neurology 2013;80:648–654
GLOSSARY
AD5 Alzheimer disease; ADNI5 Alzheimer’s Disease Neuroimaging Initiative; CI5 confidence interval;MCI5mild cognitive
impairment;MCI-P 5mild cognitive impairment–progressed;MCI-S 5 mild cognitive impairment–static;MMSE 5Mini-Men-
tal State Examination; KN-BSI 5 robust boundary shift integral.
Alzheimer disease (AD) is associated with higher rates of brain tissue loss than normal aging,1 with the
rate inmild cognitive impairment (MCI) falling somewhere in between.2 This implies increases in the
rate of tissue loss (i.e., acceleration) as the individual progresses from normal to MCI and then on to
dementia due to AD.3,4 A sigmoidal model of tissue loss in AD5 has been proposed that suggests the
rate of tissue loss first accelerates, then remains constant, and finally decelerates; however, detailed
data about how the rates of regional and global atrophy change over time are lacking. Assessing how
rates of atrophy change in the transition from normal aging through early cognitive impairment and
on to dementia due to AD is important for understanding the presymptomatic period of AD, which
is increasingly considered as a potential therapeutic window for disease-modification trials.
A number of studies have investigated acceleration in regional and global atrophy rates in normal
aging,MCI, and clinically diagnosed AD, with most modeling tissue loss as a function of age or time
from a particular clinical stage (e.g., at the time of AD dementia diagnosis or Mini-Mental State
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Examination [MMSE] score).3,4,6–8 Other stud-
ies have modeled the tissue loss as a function of
time from study baseline.9–11 The Alzheimer’s
Disease Neuroimaging Initiative (ADNI) pro-
vides an opportunity to investigate the time
course of atrophy because of its large size and
consistent longitudinal imaging. Herein, we use
data from the ADNI to quantify the regional
and global cerebral atrophy rates and accelera-
tion in rates in healthy controls and MCI sub-
jects with up to 3 years of follow-up and subjects
clinically diagnosed with mild AD with up to 2
years of follow-up.
METHODS Subjects. Data used in the preparation of this arti-
cle were obtained from the ADNI database (adni.loni.ucla.edu) (see
appendix e-1 on the Neurology® Web site at www.neurology.org).
For up-to-date information, see www.adni-info.org.
Our image data consisted of 0-, 6-, 12-, 18-, 24-, and 36-month
T1-weighted magnetic resonance scans of healthy controls, subjects
with MCI, and subjects with clinically diagnosed AD downloaded
from the ADNI database (http://www.loni.ucla.edu/ADNI) over
the course of the ADNI study, with the latest download in December
2011. The individual ADNI subject identifiers and time points used
in this study can be found in appendix e-2.
Standard protocol approvals, registrations, and patient
consents. The ADNI was approved by the institutional review
board at each site and was compliant with the Health Insurance
Portability and Accountability Act. Written consent was obtained
from all participants.
Image acquisition and preprocessing. Each individual was
scanned with a number of sequences, but for this study we used
the T1-weighted volumetric scans. Representative imaging parame-
ters were as follows: repetition time5 2,300 milliseconds; inversion
time5 1,000 milliseconds; echo time5 3.5 milliseconds; flip angle
5 8°; field of view 5 240 3 240 mm; and 160 sagittal 1.2-mm-
thick slices and a 192 3 192 matrix yielding a voxel resolution of
1.25 3 1.25 3 1.2 mm, or 180 sagittal 1.2-mm-thick slices with a
256 3 256 matrix yielding a voxel resolution of 0.94 3 0.94 3
1.2 mm. The full details of the ADNI MRI protocol have
been previously described,12 and are listed on the ADNI
Web site (http://www.loni.ucla.edu/ADNI/Research/Cores/). Each
examination underwent a quality-control evaluation at the Mayo
Clinic (Rochester, MN). Quality control included inspection of each
incoming image file for protocol compliance, clinically significant
medical abnormalities, and image quality. The images also underwent
internal quality control at the Dementia Research Centre, and those
with significant motion artifacts causing severe blurring at the tissue
boundaries were excluded from the current study. Therefore, only
subjects with a usable baseline scan and at least one usable follow-
up scan were included in the current study. The T1-weighted volu-
metric scans that passed the quality control were processed using the
standard ADNI image processing pipeline, which included the correc-
tions of gradient warping,13 B1 nonuniformity,14 intensity nonunifor-
mity,15 and scanner-drift scaling.16
Volume-loss measurement. Volume loss in the whole brain, hip-
pocampus, and lateral ventricles between every pair of scans for each
subject was measured using the robust boundary shift integral
(referred to as KN-BSI),17,18 as described below. The whole brain
and the hippocampi in each image were automatically delineated
using multiple atlas propagation and segmentation,19,20 and the lateral
ventricles were semiautomatically delineated using theMedical Image
Display and Analysis Software.21 The images from all time points of
each subject were affinely registered into a middle position,22 in order
to provide consistent volume-loss estimation over multiple time
points. Symmetric differential bias correction was performed on the
transformed images.22,23 Volume loss between any 2 images was cal-
culated by KN-BSI18 over the whole brain, the hippocampus, and the
lateral ventricles.
Statistical analysis. Baseline characteristics of subjects with usable
scans were compared with those of subjects without usable scans, sep-
arately in each group, using t tests (for age), Wilcoxon rank sum tests
(for MMSE), and Fisher exact tests (for gender and APOE e4 status).
Separately for each group, annualized atrophy rates were calcu-
lated for 0–12, 12–24, and 24–36 months using the corresponding
scan pairs, accounting for the interval in days between the scans.
Whole-brain and hippocampal atrophy rates were expressed as per-
centage of initial volume, whereas the ventricular expansion rate
was expressed as absolute loss in milliliters. We used the sum of the
volume losses in the left and right hippocampi as the total loss in the
hippocampus. Separately in each subject group, logistic regression
models were used to investigate whether atrophy during 0–12
months was predictive of availability of scan pairs between 12–24
and 24–36 months.
To test for and estimate acceleration in atrophy rates, linear
mixed models were fitted separately in each subject group to all of
the available direct measures of loss between scans from 2 time
points.24 The model contained fixed effects of time and time squared
(to allow for acceleration), and random subject effects of time. The
latter accommodates the repeated measures from subjects, and allows
the (linear) atrophy rate to vary between subjects. No constant terms
were included, consistent with an assumption that the loss between 2
scans acquired on the same day should on average be zero. We fitted
models on the logarithmic scale for the whole brain and hippocam-
pus, where zero acceleration corresponds to constant percentage atro-
phy per year and on the absolute scale for the ventricles, where zero
acceleration implies a constant absolute loss per year. Models were
fitted by maximum likelihood using the xtmixed command in Stata
12.1 (StataCorp, College Station, TX). Maximum likelihood esti-
mates are consistent provided that atrophy measures are missing at
random (i.e., the probability that a measurement is missing is inde-
pendent of the measurement itself, given observed data).25
RESULTS We downloaded MRI scans of 840 subjects,
and excluded 74 subjects who had only baseline scans
and 53 subjects who failed our internal quality control.
Although there was evidence (p 5 0.047) that APOE
e4 status of the excluded AD subjects (16 noncarriers, 18
heterozygotes, and 2 homozygotes) was different from
the included AD subjects (49 noncarriers, 73 heterozy-
gotes, and 34 homozygotes), there was no evidence that
the 713 subjects included in this study were different
from the 127 excluded subjects regarding age, MMSE
score, gender, or APOE e4 status in other groups (p .
0.10, all other tests). Table 1 shows the demographics of
the 713 subjects and the number of scan pairs available
(for consecutive scans) by subject group. As expected, the
number of subjects with scans available decreased as the
study progressed. Although not statistically significant,
logistic regression analyses (run separately by subject
group) suggested that those controls and AD subjects
Neurology 80 February 12, 2013 649
with higher whole-brain atrophy rates between 0 and 12
months were less likely to have a 12- to 24-month scan
pair available (odds ratio for 1% increase in 0- to 12-
month brain atrophy in controls 0.81 [95% confidence
interval {CI} 0.42, 1.54], p5 0.52, and in AD subjects
0.70 [95%CI 0.42, 1.17], p5 0.18). There was also the
suggestion that those MCI and AD subjects with higher
rates of brain atrophy between 0 and 12 months were
less likely to have a 24- to 36-month scan pair available
(odds ratio in controls 0.71 [95% CI 0.41, 1.22], p 5
0.21, and in MCI subjects 0.83 [95% CI 0.62, 1.13],
p5 0.24). This suggests that those subjects who under-
went scanning at 24 and 36 months may have system-
atically lower whole-brain atrophy rates than those who
did not, and that estimates of atrophy rates in the latter
part of the study based on those with scans available at
the later time points may be biased as estimates of the
population mean rate.
In table 2, we report mean (and 95% CI) atrophy
rates using data only from subjects who had scan pairs
available for all periods: 0–12, 12–24, and 24–36
months. Although these rates may be biased downward,
they are more likely to give an unbiased representation
of how rates change over time than if rates were pre-
sented for each period based on scan pairs available for
that period. A further limitation of these estimates is that
they are based on a much smaller subset of subjects, and
consequently they are less precise. Table 2 also shows
linear mixed model–based estimates of atrophy rate for
the period, using information from all subjects. As
expected, atrophy rates (and ventricular enlargement)
are highest in AD subjects, lowest in controls, with
MCI subjects in between. Without considering statisti-
cal significance, the means in table 2 suggest that
atrophy rates (brain, hippocampal, and ventricular
enlargement) are increasing in both the MCI and AD
subjects over time. In controls, the only consistent
increase is for hippocampal rates.
Table 3 shows the model-estimated atrophy rates
and acceleration, and plots of the corresponding data
on an individual basis are included in the supplemental
material (see figures e-1 and e-2). For whole-brain atro-
phy, there was no evidence of acceleration (on average)
in any group. Furthermore, the 95% CIs for the accel-
eration are narrow for controls andMCIs, suggesting we
can be reasonably confident that if average whole-brain
atrophy acceleration differs in truth from zero in these
groups, it is very close to zero. There was statistically
significant evidence of acceleration for hippocampal vol-
ume loss in MCI subjects (p 5 0.037), with rates esti-
mated to increase on average (across subjects) by 0.22%/
year2 (95% CI 0.01, 0.42). There was evidence of accel-
eration in rates of ventricular enlargement in MCI (p5
0.001) and AD (p , 0.001) subjects, with rates esti-
mated to increase by 0.27 mL/year2 (95% CI 0.12,
0.43) and 0.88 mL/year2 (95% CI 0.47, 1.29) in
MCI and AD subjects, respectively.
Post hoc analysis. We hypothesized that the observed
acceleration in hippocampal rates in MCI subjects was
a manifestation of those MCI subjects who progressed
to a clinical diagnosis of AD during the study.We there-
fore performed a post hoc analysis in 2 subgroups of
MCI subjects: MCI-P (MCI subjects that progressed
Table 1 Demographics and MRI data of controls and subjects with MCI and AD for the main analysis, and MCI-S and MCI-P subjects for the
post hoc analysisa
Main analysis Post hoc analysis
Control, n 5 205 MCI, n 5 352 AD, n 5 156 MCI-S, n 5 185 MCI-P, n 5 147
No. of men (%) 109 (53) 225 (65) 83 (53) 121 (65) 88 (60)
Age, y 76.0 (5.1) 75.0 (7.2) 74.9 (7.7) 75.6 (7.3) 74.6 (6.9)
MMSE score, of 30 29.1 (1.0) 27.0 (1.8) 23.4 (1.9) 27.2 (1.8) 26.7 (1.7)
Education, y 16.0 (2.87) 15.7 (2.98) 14.8 (3.09) 15.7 (3.15) 15.7 (2.85)
No. of APOE e4 heterozygotes (%) 50 (24.3) 151 (42.9) 73 (46.8) 70 (37.8) 76 (51.7)
No. of APOE e4 homozygotes (%) 5 (2.4) 43 (12.2) 34 (21.8) 16 (8.6) 26 (17.7)
No. of scan pairs
0–6 mo 188 315 141 162 134
6–12 mo 173 272 112 131 126
12–18 mo — 241 — 120 110
18–24 mo — 201 — 100 90
12–24 mo 142 207 80 101 96
24–36 mo 108 131 — 59 64
Abbreviations: AD 5 Alzheimer disease; MCI 5mild cognitive impairment; MCI-P 5MCI subjects observed to progress to a clinical diagnosis of AD within 3
years; MCI-S 5 MCI subjects observed to remain in MCI within 3 years; MMSE 5 Mini-Mental State Examination.
aData are mean (SD) unless stated otherwise.
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to a clinical diagnosis of AD within 3 years) and MCI-S
(MCI subjects that remained in MCI within 3 years).
Table 1 shows the demographics of the subjects accord-
ing to the clinical progression of the disease, MMSE
score at baseline, and the number of scan pairs available.
The mean atrophy rates of the MCI-S subjects were
more similar to controls, whereas the mean atrophy rates
of MCI-P subjects were more similar to AD subjects
(see table 4). There was statistically significant evidence
of acceleration for hippocampal loss in MCI-P subjects
(0.50%/year2 [95%CI 0.17, 0.83], p5 0.003), but not
in MCI-S subjects (20.02%/year2 [95% CI 20.28,
0.25], p 5 0.91) (see table 5), and an interaction test
formally comparing these showed evidence that they
differed (p 5 0.038). Although not statistically signifi-
cantly different (p5 0.38), the estimated acceleration in
ventricular expansion was also greater in the MCI-P
subjects (0.37 mL/year2 [95% CI 0.10, 0.65], p 5
0.007) than in the MCI-S subjects (0.22 mL/year2
[95% CI 0.05, 0.40], p 5 0.011).
DISCUSSION Using data from the ADNI, we have
investigated acceleration in rates of whole-brain and hip-
pocampal atrophy and ventricular enlargement, using
Table 2 Annualized atrophy rate in whole brain, hippocampus, and ventricles according to time period relative to baseline, and corresponding














(95% CI), n 5 156
Brain atrophy rate, %/y
0–12 mo 0.50 (0.39, 0.61) 0.62 (0.55, 0.69) 0.89 (0.75, 1.02) 1.02 (0.94, 1.09) 1.35 (1.19, 1.51) 1.46 (1.34, 1.59)
12–24 mo 0.76 (0.65, 0.86) 0.60 (0.56, 0.65) 0.99 (0.83, 1.14) 1.03 (0.96, 1.09) 1.58 (1.42, 1.74) 1.55 (1.41, 1.68)
24–36 mo 0.47 (0.34, 0.60) 0.59 (0.52, 0.67) 1.07 (0.90, 1.24) 1.04 (0.94, 1.13) — —
Hippocampal atrophy rate, %/y
0–12 mo 1.22 (0.86, 1.58) 1.26 (1.01, 1.51) 3.54 (3.00, 4.08) 3.31 (3.00, 3.62) 5.38 (4.68, 6.08) 5.42 (4.89, 5.95)
12–24 mo 1.52 (1.10, 1.94) 1.32 (1.15, 1.49) 3.59 (2.92, 4.26) 3.52 (3.24, 3.80) 5.87 (5.14, 6.60) 5.88 (5.29, 6.47)
24–36 mo 1.64 (1.10, 2.17) 1.38 (1.11, 1.65) 3.78 (3.22, 4.35) 3.73 (3.36, 4.10) — —
Ventricular expansion rate, mL/y
0–12 mo 1.29 (1.05, 1.53) 1.41 (1.20, 1.62) 2.44 (1.98, 2.91) 2.83 (2.55, 3.11) 4.31 (3.55, 5.08) 4.48 (3.85, 5.11)
12–24 mo 1.72 (1.38, 2.05) 1.53 (1.36, 1.71) 2.78 (2.33, 3.23) 3.10 (2.84, 3.36) 5.48 (4.67, 6.28) 5.36 (4.69, 6.03)
24–36 mo 1.49 (1.09, 1.90) 1.66 (1.43, 1.89) 3.43 (2.91, 3.95) 3.37 (3.05, 3.70) — —
Abbreviations: AD 5 Alzheimer disease; CI 5 confidence interval; MCI 5 mild cognitive impairment.
a The mean (and 95% CI) atrophy rates were calculated using data only from subjects with available scan pairs for months 0–12, 12–24, and 24–36,
whereas the model estimates were calculated using all the data.
Table 3 Model-estimated atrophy rate at baseline and acceleration rate based on linear mixed modelsa
Control, n 5 205 MCI, n 5 352 AD, n 5 156
Brain
Atrophy rate, baseline, %/y 0.63 (0.53, 0.72) 1.01 (0.92, 1.10) 1.41 (1.23, 1.59)
Acceleration in rate, %/y2 20.01 (20.07, 0.05) 0.01 (20.04, 0.06) 0.09 (20.07, 0.25)
p Value for acceleration 0.68 0.72 0.26
Hippocampus
Atrophy rate, baseline, %/y 1.22 (0.90, 1.55) 3.20 (2.82, 3.57) 5.19 (4.44, 5.94)
Acceleration in rate, %/y2 0.06 (20.13, 0.26) 0.22 (0.01, 0.42) 0.49 (20.20, 1.17)
p Value for acceleration 0.53 0.037 0.16
Ventricles
Expansion rate, baseline, mL/y 1.34 (1.09, 1.60) 2.69 (2.38, 3.01) 4.04 (3.34, 4.75)
Acceleration rate, mL/y2 0.13 (20.004, 0.26) 0.27 (0.12, 0.43) 0.88 (0.47, 1.29)
p Value for acceleration 0.06 0.001 ,0.001
Abbreviations: AD = Alzheimer disease; MCI = mild cognitive impairment.
aData are mean (95% confidence interval).
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3-year follow-up data on controls and subjects with
MCI and 2-year follow-up data for subjects with AD.
We have assessed acceleration using all available data
by using linear mixed models. The clinically defined
groups of subjects—controls, MCI, and AD—showed
the expected group differences in mean rates of atrophy
at baseline: brain atrophy rates were ;2.4 times greater
in the AD subjects than in the controls, ventricular
enlargement was ;3 times greater, and hippocampal
atrophy was ;4.3 times greater (table 3). The MCI
group rates fell almost exactly halfway between the
AD and control means for each of the measures.
Hippocampal atrophy in subjects with MCI was esti-
mated to accelerate by 0.22%/year2 (p 5 0.037) on
average. Furthermore, in the subjects with MCI who
subsequently were given a diagnosis of AD, the acceler-
ation was twice this at 0.50%/year2 (p5 0.003) and was
very similar to that seen in the AD group (0.49%/year2,
p5 0.16). This suggests that the observed acceleration of
hippocampal loss in MCI subjects is mainly driven by
the MCI subjects that were observed to progress to clin-
ical AD within 3 years. Although the estimated hippo-
campal acceleration in AD subjects was moderately large,
there was no statistically significant evidence that it dif-
fered from zero. However, this may be because of
reduced power due to the shorter period of follow-up
(only 2 years as opposed to 3 for the MCI group) and/or
greater heterogeneity in the AD group, e.g., a proportion
of AD subjects may no longer be accelerating in hippo-
campal atrophy as suggested in the sigmoid model.5
As for ventricular expansion, the rates in MCI and
AD subjects were estimated to accelerate at 0.27 and
0.88 mL/year2, respectively.
Previous studies investigating the time course of hip-
pocampal volume loss as a function of time from baseline
have reported conflicting results.9,10,26 Using 0-, 6-, and
12-month magnetic resonance scans from the ADNI,
hippocampal atrophy rates were estimated to accelerate
by 26.5 mm3/year2 (or 1.6%) in subjects with AD and
12.1 mm3/year2 (or 0.6%) in subjects with MCI, but
remained constant in controls.9 Another study found
that hippocampal atrophy rate in controls (aged 49–85
years) accelerated from 30mm3/year to 124mm3/year in
approximately 15 months,10 although the annual per-
centage change from the first to second follow-up was
approximately 4%, which was similar to the rates in AD
subjects reported by an ADNI study.9 Such acceleration
may be driven by the older control subjects. In addition,
accelerating hippocampal atrophy was found in the con-
trol,MCI, and AD subjects with AD-like CSFmolecular
profiles using 0-, 6-, and 12-month magnetic resonance
scans from ADNI.11 However, using 0-, 6-, and 12-
month magnetic resonance scans from the controls and
MCI subjects in ADNI, the intercept of the regression
line assuming no acceleration fitted to the volume loss of
the hippocampus at 6 and 12months was close to zero.26
This implies that the atrophy rates in controls and MCI
subjects stay nearly the same over 1 year. Differences in
results between studies regarding acceleration may be
attributable to differences in the number of subjects,
the number of time points, and the hippocampal
segmentation protocol used. To address the latter, the









(95% CI), n 5 147
Brain atrophy rate, %/y
0–12 mo 0.59 (0.42, 0.76) 0.82 (0.74, 0.91) 1.17 (0.98, 1.37) 1.25 (1.13, 1.38)
12–24 mo 0.86 (0.66, 1.07) 0.83 (0.76, 0.90) 1.20 (0.96, 1.44) 1.28 (1.18, 1.38)
24–36 mo 0.82 (0.59, 1.05) 0.83 (0.72, 0.94) 1.37 (1.13, 1.62) 1.30 (1.16, 1.45)
Hippocampal atrophy rate, %/y
0–12 mo 2.70 (1.94, 3.46) 2.58 (2.22, 2.95) 4.51 (3.77, 5.26) 4.26 (3.79, 4.73)
12–24 mo 2.63 (1.67, 3.59) 2.57 (2.24, 2.90) 4.88 (3.95, 5.80) 4.73 (4.33, 5.14)
24–36 mo 2.66 (1.80, 3.51) 2.55 (2.09, 3.01) 5.11 (4.40, 5.82) 5.21 (4.65, 5.76)
Ventricular expansion rate, mL/y
0–12 mo 1.64 (1.16, 2.13) 2.27 (1.93, 2.60) 3.29 (2.53, 4.06) 3.57 (3.12, 4.02)
12–24 mo 2.39 (1.89, 2.89) 2.49 (2.17, 2.81) 3.39 (2.64, 4.15) 3.94 (3.54, 4.35)
24–36 mo 2.16 (1.75, 2.56) 2.71 (2.32, 3.10) 3.75 (3.10, 4.39) 4.32 (3.80, 4.84)
Abbreviations: CI 5 confidence interval; MCI 5mild cognitive impairment; MCI-P 5MCI subjects observed to progress to a
clinical diagnosis of Alzheimer disease within 3 years; MCI-S 5 MCI subjects observed to remain in MCI within 3 years.
a The mean (and 95% CI) atrophy rates were calculated using data only from subjects with available scan pairs for months
0–12, 12–24 and 24–36, whereas the model estimates (95% CI) were calculated using all the data.
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“harmonization of hippocampal segmentation” project
was recently set up to develop a harmonized protocol
that aims to reduce the present heterogeneity in hippo-
campal segmentation protocols.27
Many studies have investigated the time course
of brain tissue loss as a function of age or other
characteristics.3,4,6–8,28,29 Using data from young
adult familial AD patients, hippocampal atrophy was
estimated to accelerate by 0.40%/year2 (95% CI 0.17,
0.63), which is similar to our estimate of 0.49%/year2.4
In the same study, the authors found evidence that
whole-brain atrophy rates accelerated by 0.26%/year2
(95% CI 0.16, 0.37), an estimate that falls just outside
the 95% CI we obtained in this study. This might be
attributable to a more aggressive onset to the familial
disease—perhaps consistent with an age at onset that is
some 30 or 40 years earlier than the age at onset in late-
onset sporadic AD in ADNI—or to the fact that the
clinically defined AD (dementia thought to be due to
AD) group in ADNI inevitably contains a proportion of
subjects who do not have AD pathologically.
Recently it was hypothesized that the dynamics of
cerebral tissue loss within individuals follows a nonlinear
and sigmoidal trajectory.5 Several studies have attempted
to fit sigmoidal models for the trajectory of cerebral
tissue loss (e.g., hippocampus and cortical thickness)
using cross-sectional data from ADNI.11,30,31 The sig-
moidal model implies that atrophy rates within a subject
initially increase from zero, remain constant for a period,
and then eventually decrease to zero. In the current
study, we modeled the trajectory of cerebral tissue loss
in each disease group using longitudinal data from AD-
NI over a 2- or 3-year period. Our linear mixed model
allowed for atrophy rates to vary between subjects, but
assumed that any acceleration was the same for all sub-
jects. Further analysis with longer follow-up will permit
models to be fitted that allow acceleration (or decelera-
tion) in rates to vary both within and between subjects,
which may provide evidence regarding the validity of
different models of progression.
Our analysis has a number of strengths and limita-
tions. Statistical power to detect acceleration in atrophy
rates is strongly affected by the length of time over which
subjects are followed, which was relatively short, partic-
ularly for the AD subjects. Despite this, our estimates of
acceleration have relatively narrow CIs. A proportion of
subjects in each group had missing scans at one or more
follow-up time points, causing a loss of information and
potentially biasing our results. However, we have used a
statistical modeling technique that accommodates such
missingness under the missing at random assumption.
We have used a consistent atrophy measurement tech-
nique that treats each time point equally, which avoids
bias toward any particular time point. Our analysis
has used data from a large number of subjects with stan-
dardized and consistent protocols used for imaging and
diagnosis.
Overall, we have found evidence of acceleration in
hippocampal atrophy rates in subjects with MCI in
the ADNI. This acceleration seems to be driven by those
subjects with MCI who subsequently received a clinical
diagnosis of AD dementia within 3 years. The rate of
acceleration of hippocampal atrophy is relatively slow
compared with the difference in atrophy rates in con-
trols and clinical AD. This suggests a long period of
transition to the pathologic losses seen in clinical AD,
provided acceleration in rates is constant. Rates of ven-
tricular enlargement were found to increase over time in
both MCI and AD subjects. Our findings give further
motivation for future longitudinal studies that will
enable investigation of how atrophy rates evolve
throughout the course of AD.
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